Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Real-world evidence of venetoclax vs ibrutinib vs idelalisib

Toby Eyre • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib Venetoclax

Toby Eyre, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, highlights the first real-world evidence of venetoclax vs ibrutinib vs idelalisib in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Toby Eyre

3:07
Advancing treatment for patients with Richter's transformation
Toby Eyre • 29 Nov 2023
3:07
Induction & maintenance therapy in elderly patients with MCL: insights from the MCL-R2 Elderly trial
Toby Eyre • 29 Nov 2023
2:38
The BOVen trial: MRD-guided obinutuzumab, zanubrutinib and venetoclax regimen in TP53-mutated MCL
Toby Eyre • 29 Nov 2023
3:00
FLAIR trial: improved outcomes with MRD-guided ibrutinib plus venetoclax in CLL compared to FCR
Toby Eyre • 29 Nov 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals